Medically-Assisted Treatment (MAT)

Oregon Contact:

John W. McIlveen, Ph.D., LMHC
Operations and Policy Analyst/State Opioid Treatment Authority (SOTA)
Manager/Health Professionals’ Service Program (HPSP)
Oregon Health Authority
Health Systems Division/Operations & Policy
500 Summer St. NE E86
Salem, OR 97301

Oregon Health Authority- Opioid

What is MAT?

Buprenorphine for Opioid Use Disorder: SAMHSA Advisory

Medication-assisted treatment (MAT) is an important part of an effective response to opioid use disorder and has been found to reduce morbidity and mortality, decrease overdose deaths, reduce transmission of infectious disease, increase treatment retention, improve social functioning, and reduce criminal activity.
This Advisory reviews current information on the use of sublingual and transmucosal buprenorphine for MAT of opioid use disorder. Topics include new formulations of buprenorphine, the effectiveness and safety of buprenorphine treatment, contraindications and cautions (including medication interactions), informed consent and treatment agreements, treatment monitoring, and indications of diversion and misuse.

NDCI Web-Training Resource for Drug Treatment Courts

Nine-module course: